title: [Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes].
abstract: We examined the behavioral pharmacological properties of six benzodiazepine (omega) receptor ligands including brotizoram, nitrazepam, quazepam, rilmazafone, zolpidem and zopiclone and the binding of these drugs with omega receptor subtypes. Behavioral tests were performed at the time of the maximal effects induced by each drug following its oral administration to mice. All of these drugs dose-dependently induced impairment of motor coordination as rotarod performance and potentiation of thiopental-induced anesthesia as hypnotic effect. The hypnotic effects of rilmazafone, whose major metabolites were bound to both omega1 and omega2 receptors with high affinity, and omega1 selective quazepam were about 20 times more effective than the induction of motor impairments when compared with ED50 values. However, there was no difference between the ED50 values of omega1 selective zolpidem alone in these two tests. An antianxiety efficacy of zolpidem was relatively weak unlike that of other drugs in the elevated plus-maze. It has been reported that omega2, but not omega1, receptors are associated with motor impairment and anxiolytic effect. The weak anxiolytic effect of zolpidem supports the previous hypothesis. However, the strong motor incoordination of zolpidem suggests that not only omega2 but also omega1 receptors are related to motor impairment unlike the previous hypothesis.
authors.affiliation: Pharmaceutical Research & Development Division, Shionogi & Co., Ltd, Osaka, Japan. mituru.yasui@shionogi.co.jp
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Yasui
authors.forename: Akira
authors.initials: A
authors.lastname: Kato
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kanemasa
authors.forename: Shunji
authors.initials: S
authors.lastname: Murata
authors.forename: Kohei
authors.initials: K
authors.lastname: Nishitomi
authors.forename: Katsumi
authors.initials: K
authors.lastname: Koike
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Tai
authors.forename: Shunji
authors.initials: S
authors.lastname: Shinohara
authors.forename: Miwa
authors.initials: M
authors.lastname: Tokomura
authors.forename: Masahito
authors.initials: M
authors.lastname: Horiuchi
authors.forename: Kohji
authors.initials: K
authors.lastname: Abe
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000378:metabolism / Q000494:pharmacology*; D001569:Benzodiazepines / Q000378:metabolism / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006993:Hypnotics and Sedatives / Q000378:metabolism / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000378:metabolism / Q000502:physiology*; D013874:Thiopental / Q000494:pharmacology; D013997:Time Factors
chemical_list: D014151:Anti-Anxiety Agents; D006993:Hypnotics and Sedatives; D011963:Receptors, GABA-A; D001569:Benzodiazepines; D013874:Thiopental